HOME >> BIOLOGY >> NEWS
Fighting the spread of sudden oak death

KINGSTON, R.I. March 4, 2002 To stop the spread of an exotic fungus that is killing oak trees in northern California, a University of Rhode Island plant pathologist has been tapped to study the newly-discovered pathogen called sudden oak death -- to better understand how it works.

Larry Englander, URI associate professor of plant pathology, is an expert on the closest known relative of the killer fungus. So he was asked by the U.S. Department of Agriculture and the U.S. Forest Service to quickly determine the parameters to its growth and survivability.

Sudden oak death is a water mold fungus that is causing an oozing canker on the trunk of oak trees from Big Sur, Calif. to the Oregon border. Trees infected with the fungus typically die within two or three months. Discovered in 1995 but only identified last year, the fungus has killed more than 100,000 trees and baffled scientists trying to understand it.

"Its so brand new that virtually nothing is known about it," said Englander. "Its still a mystery as to how it got to California. I think it needs to be in a moist environment, and this area of coastal California is like a rainforest -- very lush growth, hilly, with fog banks and rain a good part of the winter."

While the fungus has already had a devastating effect on the oak forests of California, there is an even greater concern that it could find its way across the country and wipe out the eastern forests. Scientists have tested several species of eastern oaks to see if they are susceptible to the fungus, and many are, especially red oaks.

"The fungus can definitely move from plant to plant, but that would likely restrict it to the west. Or it could be self-limiting and not move beyond its current range," explained Englander. "The big concern, though, is that people could transport it long distances either by moving plants around or by tracking infected mud from one place to another."

Sudden oak death has recently be
'"/>

Contact: Todd McLeish
tmcleish@uri.edu
401-874-7892
University of Rhode Island
4-Mar-2002


Page: 1 2 3

Related biology news :

1. Fighting Mycobacterium tuberculosis with structural proteomics
2. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
3. Fighting the battle of the bulge in children
4. Fighting breast cancer at the molecular level
5. Fighting Fungi
6. Fighting skin cancers with computers and technology
7. Fighting diabetes: UD researchers move closer to chip-based control of smart, implantable insulin pumps
8. Trash From Crop-Processing Plant Harvested For Disease-Fighting Agents
9. Studies At Cedars-Sinai Confirm Identity Of An Elusive Receptor In Human Cells -- A Breakthrough In Understanding, Fighting Septic Shock
10. Chemical Contaminants May Inhibit Cancer-Fighting White Blood Cells
11. Radioactive Beads Latest Weapon In Fighting Cancer In Dogs, Cats

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Fighting the spread sudden oak death

(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: